Skip to main content
logo
Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
1.320
-0.160 (-10.81%)
At close: Jul 31, 2026, 4:00 PM EDT
1.410
+0.090 (6.82%)
Pre-market: Aug 3, 2026, 5:35 AM EDT

Biodexa Pharmaceuticals Cash Flow Statement

Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-6.38-5.73-7.08-7.66-5.46
Depreciation & Amortization
0.190.250.280.340.4
Stock-Based Compensation
0.170.280.030.120.09
Other Adjustments
-1.99-3.46-0.85-1.06-1.58
Change in Receivables
2.63-5.980.370.01-0.49
Changes in Accounts Payable
-0.912.24-0.210.36-0.13
Changes in Income Taxes Payable
0.710.130.850.681.16
Changes in Other Operating Activities
---0.210.16-
Operating Cash Flow
-5.59-12.26-6.83-7.05-6.01
Operating Cash Flow Growth
-----
Capital Expenditures
-0-0.01-0.03-0.06-0.32
Sale of Property, Plant & Equipment
0.02-00.020.04
Purchases of Intangible Assets
-0.69-0.77-0.24--
Other Investing Activities
0.090.18-0.01-0.18-
Investing Cash Flow
-0.58-0.6-0.27-0.22-0.28
Long-Term Debt Issued
-0.450.43---
Long-Term Debt Repaid
-0.25-0.19-0.19-0.18-0.22
Net Long-Term Debt Issued (Repaid)
-0.70.25-0.19-0.18-0.22
Issuance of Common Stock
13.758.3110.430.249.04
Net Common Stock Issued (Repurchased)
13.758.3110.430.249.04
Other Financing Activities
-0.01--0.01-0.02-0.02
Financing Cash Flow
13.048.5610.230.058.81
Foreign Exchange Rate Adjustments
-----0.01
Net Cash Flow
6.87-4.33.14-7.222.52
Free Cash Flow
-5.59-12.27-6.85-7.11-6.33
Free Cash Flow Growth
-----
FCF Margin
---1798.43%-1017.17%-1094.81%
Free Cash Flow Per Share
-101948.00-2477390.00-21693900.00-1438750000.00-1571260000.00
Levered Free Cash Flow
-7.1-2.87-6.58-6.36-4.57
Unlevered Free Cash Flow
-8.52-6.2-6.89-6.58-5.15
SEC Filings: 10-K · 10-Q